TY - JOUR
T1 - Treatable traits in the NOVELTY study
AU - for the NOVELTY Study Investigators
AU - Agustí, Alvar
AU - Rapsomaniki, Eleni
AU - Beasley, Richard
AU - Hughes, Rod
AU - Müllerová, Hana
AU - Papi, Alberto
AU - Pavord, Ian D.
AU - van den Berge, Maarten
AU - Faner, Rosa
AU - Benhabib, Gabriel
AU - Ruiz, Xavier Bocca
AU - del Olmo, Ricardo
AU - Lisanti, Raul Eduardo
AU - Marino, Gustavo
AU - Mattarucco, Walter
AU - Nogueira, Juan
AU - Parody, Maria
AU - Pascale, Pablo
AU - Rodriguez, Pablo
AU - Silva, Damian
AU - Svetliza, Graciela
AU - Victorio, Carlos F.
AU - Rolon, Roxana Willigs
AU - Yañez, Anahi
AU - Anderson, Gary
AU - Baines, Stuart
AU - Bowler, Simon
AU - Bremner, Peter
AU - Bull, Sheetal
AU - Carroll, Patrick
AU - Chaalan, Mariam
AU - Farah, Claude
AU - Hammerschlag, Gary
AU - Hancock, Kerry
AU - Harrington, Zinta
AU - Katsoulotos, Gregory
AU - Kim, Joshua
AU - Langton, David
AU - Lee, Donald
AU - Peters, Matthew
AU - Prassad, Lakshman
AU - Reddel, Helen
AU - Sajkov, Dimitar
AU - Santiago, Francis
AU - Simpson, Frederick Graham
AU - Zhang, Min
AU - Zhang, Wei
AU - Jones, Gareth
AU - Patel, Manish
AU - Turner, Alice
PY - 2022/11/30
Y1 - 2022/11/30
N2 - Background and objective: Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real-world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of ‘asthma’, ‘COPD’ or ‘asthma + COPD’. Methods: The authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large (n = 11,226), global study that systematically collects data in a real-world setting, both in primary care clinics and specialized centres, for patients with ‘asthma’ (n = 5932, 52.8%), ‘COPD’ (n = 3898, 34.7%) or both (‘asthma + COPD’; n = 1396, 12.4%). Results: The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean ± SD of 4.6 ± 2.6, 5.4 ± 2.6 and 6.4 ± 2.8 TTs/patient in those with ‘asthma’, ‘COPD’ and ‘asthma + COPD’, respectively (p < 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity. Conclusion: These results provide the largest and most granular characterization of TTs in patients with airway diseases in a real-world setting to date.
AB - Background and objective: Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real-world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of ‘asthma’, ‘COPD’ or ‘asthma + COPD’. Methods: The authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large (n = 11,226), global study that systematically collects data in a real-world setting, both in primary care clinics and specialized centres, for patients with ‘asthma’ (n = 5932, 52.8%), ‘COPD’ (n = 3898, 34.7%) or both (‘asthma + COPD’; n = 1396, 12.4%). Results: The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean ± SD of 4.6 ± 2.6, 5.4 ± 2.6 and 6.4 ± 2.8 TTs/patient in those with ‘asthma’, ‘COPD’ and ‘asthma + COPD’, respectively (p < 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity. Conclusion: These results provide the largest and most granular characterization of TTs in patients with airway diseases in a real-world setting to date.
KW - airways
KW - allergy
KW - asthma
KW - bronchitis
KW - chronic obstructive pulmonary disease
KW - COPD
KW - emphysema
KW - smoking
U2 - 10.1111/resp.14325
DO - 10.1111/resp.14325
M3 - Article
C2 - 35861464
AN - SCOPUS:85134514840
SN - 1323-7799
VL - 27
SP - 929
EP - 940
JO - Respirology
JF - Respirology
IS - 11
ER -